Fermenta Biotech
NSE: FERMENTA · ISIN INE225B01021 · Healthcare
₹436.35−18.65 (−4.10%)
Monday 9 November, 12:56 IST. Delayed. Source: Yahoo Finance.
Price chart
₹436.35 −18.65 (−4.10%) today
The day
- Previous close
- ₹455.00
- Open
- ₹459.55
- Day high
- ₹459.55
- Day low
- ₹433.50
Listed on NSE since 4 August 2026.
Key numbers
- Market value
- ₹1,307.09 Cr
- P/E (trailing)
- 21.96
- EPS (trailing)
- ₹20.72
- Price to book
- 3.21
- Dividend yield
- 0.90%
- Debt to equity
- 0.28
- Profit margin
- 11.7%
- Beta
- -0.24
- Volume today
- 41,777
- Average volume
- 2.28 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹349.06 Cr | ₹-51.08 Cr |
| FY24 | ₹333.46 Cr | ₹-23.06 Cr |
| FY25 | ₹467.09 Cr | ₹76.86 Cr |
| FY26 | ₹523.56 Cr | ₹71.77 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹133 Cr | ₹10 Cr | – |
| Q1 FY27Apr–Jun 2026 | ₹122 Cr | ₹10 Cr | – |
Source: Fermenta Biotech’s results filed with NSE, consolidated (the whole group). Net profit is the share of Fermenta Biotech’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 |
|---|---|
| Fixed assets | ₹225 Cr |
| Investments | ₹43.65 L |
| Inventories | ₹167 Cr |
| Owed by customers | ₹124 Cr |
| Cash and equivalents | ₹30 Cr |
| Total assets | ₹696 Cr |
| Borrowings | ₹105 Cr |
| Total liabilities | ₹284 Cr |
| Shareholders’ equity | ₹418 Cr |
Source: Fermenta Biotech’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Fermenta Biotech
Fermenta Biotech Limited, together with its subsidiaries, engages in the manufacturing and marketing of chemicals, bulk drugs, enzymes, pharmaceutical formulations, and environmental solution products in India, Europe, the United States, and internationally. It operates through Chemicals/Bulk Drug and Property segments. The company offers vitamin D3, including crystalline oil, resin oil, cold water dispersible, and feed grade powder for injectables, soft gel capsules, premixes, food and beverage fortification applications; and vitamin K1, vitamin E50, phenyramidol and silicon dioxide, and fish oil cholesterol. It also provides fortified rice kernel; and Fermase PS 250 and penicillin G acylase used in manufacturing processes of various antibiotics. In addition, the company offers design, engineering, procurement, and construction of wastewater treatment plants, STPs, and ETPs, as well as operation and maintenance services. Further, it is involved in property development business; and renting and selling of properties. The company was formerly known as DIL Limited. Fermenta Biotech Limited was incorporated in 1951 and is based in Thane, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Thane
- Employees
- 630
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Fermenta Biotech in the last day or two.
Dividends and corporate actions
All companies- Dividend - Rs 3.75 Per Share
Dividend · ex-date 5 August 2026
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.